Michael A. Nauck

Feb 1, 2024 | thieme-connect.de | Michael A. Nauck

Die vorliegende Publikation von Yao et al. ist das Ergebnis eines sehr ambitionierten Forschungsvorhabens, nämlich die Wirksamkeit, aber auch die unerwünschten Arzneimittelwirkungen von inkretinbasierten Medikamenten quantitativ zu vergleichen.

Nov 7, 2023 | acpjournals.org | Ryan J Jalleh |Karen Jones |Michael A. Nauck |Michael Horowitz

Authors: Ryan J. Jalleh, MBBS; Karen L. Jones, Dip App Sc (Nuclear Medicine), PhD; Michael Nauck, MD; Michael Horowitz, MBBS, PhD, DScAffiliations: Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, South Australia, Australia (R.J.J., K.L.J., M.H.)Diabetes Endocrinology, Metabolism Section, Katholisches Klinikum Bochum, St. Josef-Hospital, Ruhr-University, Bochum, Germany (M.N.).

Jun 23, 2023 | thelancet.com | Michael A. Nauck |Medicine Greifswald |Michael Horowitz

Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.

Jun 12, 2023 | nature.com | Rubén Nogueiras |Michael A. Nauck |Matthias H. Tschöp

AbstractThe discovery and development of so-called gut hormone co-agonists as a new class of drugs for the treatment of diabetes and obesity is considered a transformative breakthrough in the field. Combining action profiles of multiple gastrointestinal hormones within a single molecule, these novel therapeutics achieve synergistic metabolic benefits. The first such compound, reported in 2009, was based on balanced co-agonism at glucagon and glucagon-like peptide-1 (GLP-1) receptors.